These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33878406)

  • 41. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample.
    Sara GE; Burgess PM; Malhi GS; Whiteford HA; Hall WC
    Aust N Z J Psychiatry; 2014 Nov; 48(11):1036-47. PubMed ID: 24819935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students.
    Sepúlveda DR; Thomas LM; McCabe SE; Cranford JA; Boyd CJ; Teter CJ
    J Pharm Pract; 2011 Dec; 24(6):551-60. PubMed ID: 22095577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States.
    Compton WM; Han B; Blanco C; Johnson K; Jones CM
    Am J Psychiatry; 2018 Aug; 175(8):741-755. PubMed ID: 29656665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prescription stimulant use is associated with earlier onset of psychosis.
    Moran LV; Masters GA; Pingali S; Cohen BM; Liebson E; Rajarethinam RP; Ongur D
    J Psychiatr Res; 2015 Dec; 71():41-7. PubMed ID: 26522870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?
    Rohatgi RK; Bos JM; Ackerman MJ
    Heart Rhythm; 2015 Aug; 12(8):1807-12. PubMed ID: 25956966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early exposure to stimulant medications and substance-related problems: The role of medical and nonmedical contexts.
    McCabe SE; Veliz P; Boyd CJ
    Drug Alcohol Depend; 2016 Jun; 163():55-63. PubMed ID: 27129621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Age differences in outcomes among patients in the "Stimulant Abuser Groups to Engage in 12-Step" (STAGE-12) intervention.
    Garrett SB; Doyle SR; Peavy KM; Wells EA; Owens MD; Shores-Wilson K; DiCenzo J; Donovan DM
    J Subst Abuse Treat; 2018 Jan; 84():21-29. PubMed ID: 29195590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls.
    van der Meer FJ; Meijer JH; Meijer CJ; van den Brink W; Velthorst E;
    Psychol Med; 2014 Jul; 44(9):1901-11. PubMed ID: 24267407
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stimulant medication for ADHD in opioid maintenance treatment.
    Abel KF; Bramness JG; Martinsen EW
    J Dual Diagn; 2014; 10(1):32-8. PubMed ID: 25392060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stimulant psychosis: systematic review.
    Curran C; Byrappa N; McBride A
    Br J Psychiatry; 2004 Sep; 185():196-204. PubMed ID: 15339823
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.
    Merkel RL
    Expert Opin Drug Saf; 2010 Nov; 9(6):917-35. PubMed ID: 20615078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Examining the Frequency of Stimulant Misuse among Patients with Primary Disorders of Hypersomnolence: A Retrospective Cohort Study.
    Mantyh WG; Auger RR; Morgenthaler TI; Silber MH; Moore WR
    J Clin Sleep Med; 2016 May; 12(5):659-62. PubMed ID: 26943713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comorbid Cannabis and Tobacco Use Disorders in Hospitalized Patients with Psychotic-Spectrum Disorders.
    Reeves LE; Gaudiano BA; Metrik J; Guzman Holst C; Morena A; Sydnor VJ; Weinstock LM; Epstein-Lubow G
    J Dual Diagn; 2018; 14(3):171-180. PubMed ID: 30265850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.
    Klassen LJ; Bilkey TS; Katzman MA; Chokka P
    Curr Drug Abuse Rev; 2012 Sep; 5(3):190-8. PubMed ID: 22571450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.
    Wigal SB
    CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Misuse of methamphetamine and prescription stimulants among youths and young adults in the community.
    Wu LT; Pilowsky DJ; Schlenger WE; Galvin DM
    Drug Alcohol Depend; 2007 Jul; 89(2-3):195-205. PubMed ID: 17257780
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective relations between melancholia and substance use disorders.
    Leventhal AM; Lewinsohn PM; Pettit JW
    Am J Drug Alcohol Abuse; 2008; 34(3):259-67. PubMed ID: 18428068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
    Wilens TE; Adler LA; Adams J; Sgambati S; Rotrosen J; Sawtelle R; Utzinger L; Fusillo S
    J Am Acad Child Adolesc Psychiatry; 2008 Jan; 47(1):21-31. PubMed ID: 18174822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychocutaneous disorders: a survey study of psychiatrists' awareness and treatment patterns.
    Jafferany M; Stoep AV; Dumitrescu A; Hornung RL
    South Med J; 2010 Dec; 103(12):1199-203. PubMed ID: 20978462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Childhood stimulant treatment and risk for later substance abuse.
    Fischer M; Barkley RA
    J Clin Psychiatry; 2003; 64 Suppl 11():19-23. PubMed ID: 14529326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.